Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALBT OTCMKTS:CPMD OTCMKTS:IMUN NASDAQ:MYNZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALBTAvalon GloboCare$2.03+0.5%$2.41$1.87▼$11.66$7.79M0.02302,125 shs66,068 shsCPMDGolden Dragon$0.00-16.7%$0.00$0.00▼$0.01$1.65M2.39193,673 shs90,000 shsIMUNImmune Therapeutics$0.09$0.09$0.07▼$1.30$7.78M0.4615,246 shs12 shsMYNZMainz Biomed$1.69+0.6%$1.68$1.30▼$16.32$7.74M0.25188,689 shs95,657 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALBTAvalon GloboCare0.00%-5.16%-6.48%-42.29%-45.21%CPMDGolden Dragon0.00%0.00%-6.25%-38.78%-68.42%IMUNImmune Therapeutics0.00%0.00%0.00%0.00%0.00%MYNZMainz Biomed0.00%-2.33%+26.32%-15.58%-88.13%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALBTAvalon GloboCare2.0857 of 5 stars0.04.00.04.33.51.70.0CPMDGolden DragonN/AN/AN/AN/AN/AN/AN/AN/AIMUNImmune TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMYNZMainz Biomed3.1584 of 5 stars3.33.00.00.03.30.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALBTAvalon GloboCare 0.00N/AN/AN/ACPMDGolden Dragon 0.00N/AN/AN/AIMUNImmune Therapeutics 0.00N/AN/AN/AMYNZMainz Biomed 2.50Moderate Buy$14.00728.40% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALBTAvalon GloboCare$1.39M5.60N/AN/A($11.37) per share-0.18CPMDGolden Dragon$820K2.01N/AN/A($0.03) per share-0.08IMUNImmune TherapeuticsN/AN/AN/AN/A($0.03) per shareN/AMYNZMainz Biomed$893.99K8.65N/AN/A$2.61 per share0.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALBTAvalon GloboCare-$7.90M-$19.96N/A∞N/A-1,451.94%N/A-75.12%11/10/2025 (Estimated)CPMDGolden Dragon-$9.91M-$0.01N/A∞N/A-423.36%N/A-34.17%N/AIMUNImmune Therapeutics-$3.54MN/A0.00∞N/AN/AN/A-544.75%N/AMYNZMainz Biomed-$21.65M-$65.60N/AN/AN/AN/AN/AN/AN/ALatest CPMD, IMUN, ALBT, and MYNZ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ALBTAvalon GloboCareN/A-$2.02N/A-$6.22N/A$0.35 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALBTAvalon GloboCareN/AN/AN/AN/AN/ACPMDGolden DragonN/AN/AN/AN/AN/AIMUNImmune TherapeuticsN/AN/AN/AN/AN/AMYNZMainz BiomedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALBTAvalon GloboCareN/A0.060.06CPMDGolden DragonN/A0.040.01IMUNImmune TherapeuticsN/AN/AN/AMYNZMainz Biomed0.141.321.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALBTAvalon GloboCare1.42%CPMDGolden DragonN/AIMUNImmune TherapeuticsN/AMYNZMainz BiomedN/AInsider OwnershipCompanyInsider OwnershipALBTAvalon GloboCare37.30%CPMDGolden Dragon1.27%IMUNImmune Therapeutics50.59%MYNZMainz BiomedN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALBTAvalon GloboCare53.84 million2.41 millionNot OptionableCPMDGolden Dragon4660.63 million652.24 millionNot OptionableIMUNImmune Therapeutics283.66 million41.34 millionNot OptionableMYNZMainz Biomed304.58 millionN/ANot OptionableCPMD, IMUN, ALBT, and MYNZ HeadlinesRecent News About These CompaniesMainz Biomed Announces Registration of ColoAlert in the United KingdomSeptember 2 at 8:01 AM | globenewswire.comMainz Biomed receives Swiss regulatory approval to market ColoAlertAugust 14, 2025 | msn.comMainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®August 13, 2025 | globenewswire.comMainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and WarrantsAugust 4, 2025 | globenewswire.comMainz Biomed files to sell 1.47M ordinary unitsJuly 31, 2025 | msn.comEQS-News: Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance CompaniesJuly 24, 2025 | finanzen.atFMainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance CompaniesJuly 23, 2025 | globenewswire.comMainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening AcquisitionJuly 15, 2025 | globenewswire.comMainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening AcquisitionJuly 15, 2025 | globenewswire.comMainz Biomed BV News (MYNZ) - Investing.comJuly 4, 2025 | investing.comMainz Biomed erhält staatliche Förderung für die Entwicklung seines innovativen Tests zur Früherkennung von BauchspeicheldrüsenkrebsJune 25, 2025 | anlegerplus.deAMainz BioMed NV: Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening TestJune 25, 2025 | finanznachrichten.deMainz Biomed BV Aktie | MYNZ Kurs | Realtime - Investing.comJune 25, 2025 | de.investing.comEQS-News: Mainz Biomed erhält staatliche Förderung für die Entwicklung seines innovativen Tests zur Früherkennung von BauchspeicheldrüsenkrebsJune 25, 2025 | boerse.deBMainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening TestJune 25, 2025 | globenewswire.comPromising Advancements in Cancer Diagnostics Propel Mainz Biomed B.V. to a Buy RatingJune 11, 2025 | tipranks.comMainz BioMed NV: Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer ProjectJune 10, 2025 | finanznachrichten.deMainz Biomed startet Machbarkeitsstudie zu Biomarker-Panel im Rahmen seines Projekts zur Behandlung von BauchspeicheldrüsenkrebsJune 10, 2025 | anlegerplus.deAMainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer ProjectJune 10, 2025 | finance.yahoo.comMainz Biomed Initiates Feasibility Phase for Non-Invasive Pancreatic Cancer Screening Test in PancAlert ProjectJune 10, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCPMD, IMUN, ALBT, and MYNZ Company DescriptionsAvalon GloboCare NASDAQ:ALBT$2.03 +0.01 (+0.50%) Closing price 04:00 PM EasternExtended Trading$2.02 0.00 (-0.25%) As of 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.Golden Dragon OTCMKTS:CPMD$0.0025 0.00 (-16.67%) As of 03:42 PM EasternCannaPharmaRX, Inc. operates in the cannabis industry in Canada. It evaluates, negotiates, acquires, and develops various cannabis cultivation projects. The company was incorporated in 1998 and is based in Calgary, Canada.Immune Therapeutics OTCMKTS:IMUN$0.09 0.00 (0.00%) As of 10/19/2023Immune Therapeutics, Inc. does not have significant operations. The company was formerly known as TNI BioTech, Inc. and changed its name to Immune Therapeutics, Inc. in October 2014. Immune Therapeutics, Inc. is based in Winter Park, Florida.Mainz Biomed NASDAQ:MYNZ$1.69 +0.01 (+0.60%) Closing price 04:00 PM EasternExtended Trading$1.67 -0.02 (-1.18%) As of 05:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Kohl’s Stock Rebound Faces a Showdown With Short Sellers What to Watch for From D-Wave Now That Earnings Are Done 3 High-Yield Stocks Just Supercharged Their Dividends MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Alphabet’s Resurgence: It's Now a Clear Market Leader Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
